The information gathered from a patient registry and biobank will help design future clinical trials in diverse populations. The two parties said the data could also help improve the design of oncology clinical trials, assist in patient recruitment efforts, and encourage the expansion of genomic profiling testing in diverse populations.

Labcorp and CCORN will also create a biobank to allow the broader oncology community to access real-world evidence and identify the sources of disparities. Labcorp said doing so will help the oncology community gain a deeper understanding of how to continue advancing personalized medicine in cancer care, thereby improving outcomes for all patients.